Anzeige
Meldung des Tages: Freitagabend nachbörslich veröffentlicht – was der Markt erst am Montag sieht

Halozyme Therapeutics Aktie News

Aktie
WKN:  A0DLHS ISIN:  US40637H1095 US-Symbol:  HALO Branche:  Biotechnologie Land:  USA
71,59 $
-1,75 $
-2,39%
60,411 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
7,44 Mrd. €
Streubesitz
-
KGV
10,83
neu: Nachhaltigkeits-Score
36 %
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 8,77: JU68DZ
Werbung

Halozyme Therapeutics News

06.08.25 - ARIVA.DE Redaktion
Dieses Biotech-Unternehmen schlägt Bayer, Evotec, Novo Nordisk & Co. um Längen!
Während Anlegerinnen und Anleger verzweifelt auf einen Turnaround der Aktien von Bayer, Evotec und Novo Nordisk warten, liefert dieser Rivale konstant Gewinne.
05.08.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS PR Newswire
23.07.25 - PR Newswire
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma PR Newswire
22.07.25 - PR Newswire
Halozyme to Report Second Quarter 2025 Financial and Operating Results
Halozyme to Report Second Quarter 2025 Financial and Operating Results PR Newswire
30.06.25 - PR Newswire
Halozyme Therapeutics Added to Russell 1000® Index
Halozyme Therapeutics Added to Russell 1000® Index PR Newswire
20.06.25 - PR Newswire
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating ...
28.05.25 - PR Newswire
Halozyme to Participate at Upcoming Investor Conferences
Halozyme to Participate at Upcoming Investor Conferences PR Newswire
28.05.25 - PR Newswire
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-​Formulated with ENHANZE® Across Multiple ...
10.05.25 - wallstreetONLINE Redaktion
Community-Rückblick: "Kann dieses verdammte Unternehmen nicht ein Mal positiv überraschen?!"
Das Hamburger Biotech-​Unternehmen Evotec hat am 06. Mai seine Zahlen zum ersten Quartal 2025 präsentiert. Die wo-​Community reagiert überwiegend enttäuscht und steht ...
06.05.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS PR Newswire
06.05.25 - wallstreetONLINE Redaktion
Enttäuschender Jahresauftakt: Evotec: Bitte nicht schon wieder!
Das Hamburger Biotech-​Unternehmen Evotec hat seine Zahlen zum ersten Quartal präsentiert. Die gefallen Anlegerinnen und Anlegern nicht, die Aktie fällt.Trotz der von Bristol-...
05.05.25 - PR Newswire
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference PR Newswire
28.04.25 - PR Newswire
Halozyme to Report First Quarter 2025 Financial and Operating Results
Halozyme to Report First Quarter 2025 Financial and Operating Results PR Newswire
28.04.25 - PR Newswire
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating ...
24.04.25 - PR Newswire
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation PR Newswire
10.04.25 - PR Newswire
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-​Formulated with ENHANZE® for Self-​Injection for Generalized Myasthenia Gravis and ...
09.04.25 - PR Newswire
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, ...
07.04.25 - PR Newswire
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-​Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-​Mutated Non-...
31.03.25 - PR Newswire
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid ...
26.02.25 - PR Newswire
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
29.01.26 -10,12%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »